SCHEMBL1719833

SCHEMBL1719833

Cn1nc(CC(=O)N2CCCC2)c2c3ccccc3c(=O)[nH]c21

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 4/20 0.49
ALDH1A1 P00352 7/20 0.49
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
SMN1; SMN2 Q16637 6/20 0.48
TSHR P16473 5/20 0.48
LMNA P02545 4/20 0.48
GAA P10253 2/20 0.48
POLB P06746 1/20 0.48
MAPT P10636 1/20 0.48
MAPK1 P28482 2/20 0.44
HPGD P15428 2/20 0.43
HSD17B10 Q99714 1/20 0.43
HTT P42858 1/20 0.39
ALPL P05186 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1720598 0.83 PARP1 (0.49) PARP1KMT2ASMN1; SMN2TSHRLMNA
SCHEMBL1719750 0.81 PARP1 (0.56) PARP1ALDH1A1KMT2AMEN1GAA
SCHEMBL4068289 0.80 PARP1 (0.55) PARP1ALDH1A1KMT2AMEN1LMNA
SCHEMBL1720503 0.80 PARP1 (0.55) PARP1
Hydrochloric Acid SCHEMBL1719747 0.79 PARP1 (0.54) PARP1ALDH1A1KMT2AMEN1GAA
SCHEMBL11278033 0.78 PARP1 (0.56) PARP1SMN1; SMN2HPGDHSD17B10KDM4E
SCHEMBL1720862 0.75 PARP1 (0.55) PARP1GAAPOLBMAPT
SCHEMBL1720121 0.74 PARP1 (0.53) PARP1KMT2AMEN1POLBKDM4E
SCHEMBL1720304 0.74 PARP1 (0.53) PARP1ALDH1A1KMT2AMEN1SMN1; SMN2
SCHEMBL4069217 0.73 PARP1 (0.50) PARP1ALDH1A1KMT2AMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1566380-B1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2012-01-11 EP disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-05-04 US disclosed
EP-1566380-A1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2005-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof PARP1, NQO1, PARP3 PARP1 1/4885ALDH1A1 169/4885KMT2A 1063/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.